Effect of multivariate process instability on principal component analysis: A case study
Journal Title: The AAPS Journal - Year 2005, Vol 7, Issue 1
Abstract
With the rising use of principal component analysis/partial least squares (PCA/PLS) in the process analytical technology (PAT) initiative of the pharmaceutical industry, it seems appropriate to view that approach from a statistical process control (SPC) perspective. The purpose of this study was to demonstrate the effect of process instability (ie, state of statistical out-of-control) on use of PCA/PLS. The demonstrated differences in results should encourage PCA/PLS users to incorporate SPC as an active part of their process analytical control (PAC) toolkit to check for stability prior to drawing conclusions based on PCA/PLS analysis.
Authors and Affiliations
Donald S. Holmes, A. Erhan Mergen
Isothermal Microcalorimetry as a Quality by Design Tool to Determine Optimal Blending Sequences
This study was designed to assess the value of isothermal microcalorimetry (ITMC) as a quality by design (QbD) tool to optimize blending conditions during tablet preparation. Powder mixtures that contain microcrystalline...
Fish Drug Analysis—Phish-Pharm: 2011 Update
Effect of N-1 and N-2 residues on peptide deamidation rate in solution and solid state
The deamidation kinetics of 7 model peptides (VYPNGA, VYGNGA, VFGNGA, VIGNGA, VGGNGA, VGPNGA, and VGYNGA) were studied at 70°C in pH 10 buffer solutions and at 70°C and 50% relative humidity in lyophilize...
Pharmacokinetic and Pharmacodynamic Modeling of a Monoclonal Antibody Antagonist of Glucagon Receptor in Male ob/ob Mice
Elevated basal concentrations of glucagon and reduced postprandial glucagon suppression are partly responsible for the increased hepatic glucose production seen in type 2 diabetic patients. Recently, it was demonstrated...
Pharma Success in Product Development—Does Biotechnology Change the Paradigm in Product Development and Attrition
The biotechnology segment of the overall biopharma industry has existed for only about 40–45 years, as a driver of new product development. This driving force was initiated with the FDA approval of recomb...